Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+β in epithelial ovarian cancer patients

Objectives: The aim of this work was to compare and analyze the diagnostic value of serum prostasin, cancer antigen 125 (CA125), lactate dehydrogenase (LDH), alpha-fetoprotein (AFP), and human chorionic gonadotropin (hCG+β) in epithelial ovarian cancer (EOC) and evaluate if their serum levels could be used as a potential diagnostic markers of EOC from benign tumors and healthy women. Materials and Methods: Preoperative serum samples of 110 women (24 healthy controls, 66 ovarian benign tumors, and 20 EOC) were tested for prostasin, CA125, AFP, and hCG+β. The level of CA125, AFP, and hCG+β serum tumor markers were determined by electrochemiluminescence immunoassay (ECLIA) and the serum level of prostasin was measured using enzyme-linked immunosorbent assay (ELISA) and LDH activity was measured by spectrophotometer and analyzed using SPSS version. Results: The Area Under the Curve (AUC) values of prostasin, CA125, LDH, AFP, and hCG+β for the discrimination of EOC from benign and healthy controls were, respectively, 0.89, 0.91, 0.77, 0.54, and 0.65, and significant increase in serum levels of prostasin, CA125, and LDH were observed for EOC compared with benign and control groups. Conclusion: The present study showed that CA125 and LDH levels of serum increased in high stages, while prostasin level was decreased in high stages. The present results indicate that prostasin, CA125, and LDH are differentially expressed in EOC than in benign and healthy control population, that may be an indicative of a better diagnostic value, with higher sensitivity and specificity. Here the authors used a multimarker approach, consisting of CA125, AFP, beta hCG, prostasin, and LDH that could provide a more accurate tool for a differential diagnosis of patients with EOC.

Epithelial ovarian cancer; Prostasin; Cancer antigen 125; Lactate dehydrogenase; Alpha-fetoprotein; Human chorionic gonadotropin.

[1] Berek J.S.: “Berek & Novak’s Gynecology”. 14thed. Philadelphia, PA: Lippincott Williams & Wilkins, 2007.

[2] Ferlay J., Soerjomataram I., Ervik M., Ervik M., Dikshit R., Eser S., Mathers C., et al.: “GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11”. Lyon, France: International Agency for Research on Cancer, 2013. Available at: http://globocan.iarc.fr

[3] Arab M., Khayamzadeh M., Tehranian A., Tabatabaeefar M., Hosseini M., Anbiaee R., et al.: “Incidence rate of ovarian cancer in Iran in comparison with developed countries”. Indian J. Cancer, 2010, 47, 322.

[4] Arab M., Khayamzadeh M., Mohit M., Hosseini M., Anbiaee R., Tabatabaeefar M., et al.: “Survival of Ovarian Cancer in Iran: 2000-2004”. Asian Pac. J. Cancer Prev., 2009, 10, 555.

[5] Leung F., Diamandis E.P., Kulasingam V.: “Current state and future implications from high-throughput technologies”. Adv. Clin. Chem., 2014, 66, 25.

[6] Engel J., Eckel R., Schubert-Fritschle G., Kerr J., Kuhn W., Diebold J., et al.: “Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate”. Eur. J. Cancer, 2002, 38, 2435.

[7] Rankin E.B., Fuh K.C., Taylor T.E., Krieg A.J., Musser M., Yuan J., et al.: “AXL is an essential factor and therapeutic target for metastatic ovarian cancer”. Cancer Res., 2010, 70, 7570.

[8] Hartge P.: “Designing early detection programs for ovarian cancer”. J. Nat. Cancer Inst., 2010, 102, 3.

[9] Willmott L.J., Fruehauf J.P.: “Targeted therapy in ovarian cancer”. J. Oncol., 2010, 2010, 740472.

[10] American Cancer Society: “General information about ovarian cancer”. Available at: http://www.cancer.org/cancer/ovariancancer/index.

[11] Kim A., Ueda Y., Naka T., Enomoto T.: “Therapeutic strategies in epithelial ovarian cancer”. J. Exp. Clin. Cancer Res., 2012, 31, 14.

[12] Ma J.X., Yan B.X., Zhang J., Jiang B.H., Guo Y., Riedel H., et al.: “PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer”. Cell Death Dis., 2014, 5, e1407.

[13] Yip P., Chen T.H., Seshaiah P., Stephen L.L., Michael-Ballard K.L., Mapes J.P., et al.: “Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers”. PLoS One, 2011, 6, e29533.

[14] Lucarelli G., Rutigliano M., Bettocchi C., Palazzo S., Vavallo A., Galleggiante V., et al.: “Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer”. J. Urol., 2013, 190, 2271.

[15] Duffy M.J., McGowan P.M., Harbeck N., Thomssen C., Schmitt M.: “uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies”. Breast Cancer Res., 2014, 16, 428.

[16] Chen L.M., Skinner M.L., Kauffman S.W., Chao J., Chao L., Thaler C.D., Chai K.X.: “Prostasin is a glycosylphosphatidylinositol- anchored active serine protease”. J. Biol. Chem., 2007, 276, 21434.

[17] López-Otín C., Matrisian L.M.: “Emerging roles of proteases in tumour suppression”. Nat. Rev. Cancer, 2007, 7, 800.

[18] Costa F.P., Batista E.L. Jr., Zelmanowicz A., Svedman C., Devenz G., Alves S., et al.: “Prostasin, a potential tumor marker in ovarian cancer: a pilot study”. Clinics (Sauo Paulo), 2009, 64, 641.

[19] Bast R.C. Jr., Klug T.L., St John E., Jenison E., Niloff J.M., Lazarus H., et al.: “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer”. N. Engl. J. Med., 1983, 309, 883.

[20] Felder M., Kapur A., Gonzalez-Bosquet J., Horibata S., Heintz J., Albrecht R., et al.: “MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress”. Mol. Cancer, 2014, 13, 129.

[21] Kim H.S., Choi H.Y., Lee M., Suh D.H., Kim K., No J.H., et al.: “Systemic inflammatory response markers and CA-125 levels in ovarian clear cell carcinoma: a two center cohort study”. Cancer Res. Treat., 2016, 48, 250.

[22 Ind T., Iles R., Shepherd J., Chard T.: “Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer
associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer”. Br. J. Obstet. Gynaecol., 1997, 104, 1024.

[23] Paramasivam S., Tripcony L., Crandon A., Quinn M., Hammond I., Marsden D., et al.: “Prognostic importance of preoperative CA- 125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study”. J. Clinical Oncol., 2005, 23, 5938.

[24] Mizejewski G.J.: “Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants”. Exp. Biol. Med. (Maywood), 2001, 226, 377.

[25] Lee Y.J., Lee S.W.: “Regression of hepatocarcinoma cells using RNA aptamer specific to alpha-fetoprotein”. Biochem. Biophys. Res. Commun., 2012, 417, 521.

[26] Awais G.M.: “Serum lactic dehydrogenase levels in the diagnosis and treatment of carcinoma of the ovary”. Am. J. Obstet. Gynecol., 1973, 116, 1053.

[27] Schneider D., Halperin R., Langer R., Bukovsky I., Herman A.: “Peritoneal fluid lactate dehydrogenase in ovarian cancer”. Gynecol. Oncol., 1997, 66, 399.

[28] Fournier T., Guibourdenche J., Evain-Brion D.: “Review: hCGs: different sources of production, different glycoforms and functions”. Placenta, 2015, 36, S60.

[29] Whittington J., Fantz C.R., Gronowski A.M., McCudden C., Mullins R., Sokoll L., et al.: “The analytical specificity of human chorionic gonadotropin assays determined using WHO International Reference Reagents”. Clin. Chim. Acta, 2010, 411, 81.

[30] Fishman W.H., Inglis N.R., Vaitukaitis J., Stolbach L.L.: “Regan isoenzyme and human chorionic gonadotropin in ovarian cancer”. Natl. Cancer Inst. Monogr., 1975, 42, 63.

[31] Stenman U-H., Alfthan H., Hotakainen K.: “Human chorionic gonadotropin in cancer”. Clin. Biochem., 2004, 37, 549.

[32] Cole L.A., Wang Y.X., Elliott M., Latif M., Chambers J.T., Chambers S.K., Schwartz P.E.: “Urinary human chorionic gonadotropin free β-subunit and β-core fragment: a new marker of gynecological cancers”. Cancer Res., 1988, 48, 1356.

[33] Heidari M.H., Bastani A., Asgary A., Malekkandi, M.: “Evaluation of prostasin levels in serum of patients with ovarian cancer as a new potential tumor marker”. Asian J. Med. Pharm. Res., 2014, 4, 53.

[34] Akbari M.E., Abachizadeh K., Khayamzadeh M., Tabatabaee M., Esnaashari F., Motlagh A.G.: “Iran cancer report”. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Qom: Darolfekr, 2008.

[35] Kuchenbaecker K.B., Ramus S.J., Tyrer J., Lee A., Shen H.C., Beesley J., et al.: “Identification of six new susceptibility loci for invasive epithelial ovarian cancer”. Nat. Genet., 2015, 47, 164.

[36] Zarogoulidis P., Tsakiridis K., Karapantzou C., Lampaki S., Kioumis I., Pitsiou G., et al.: “Use of proteins as biomarkers and their role in carcinogenesis”. J. Cancer, 2015, 6, 9.

[37] Bandiera E., Romani C., Specchia C., Zanotti L., Galli C., Ruggeri G., et al.: “Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management”. Cancer Epidemiol. Biomarkers Prev., 2011, 20, 2496.

[38] Havrilesky L.J., Whitehead C.M., Rubatt J.M., Cheek R.L., Groelke J., He Q., et al.: “Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence”. Gynecol. Oncol., 2008, 110, 374.

[39] Menon U., Griffin M., Gentry-Maharaj A.: “Ovarian cancer screening—current status, future directions”. Gynecol. Oncol., 2014, 132, 490.

[40] Chen L.M., Hodge G.B., Guarda L.A., Welch J.L., Greenberg N.M., Chai K.X.: “Down
regulation of prostasin serine protease: A potential invasion suppressor in prostate cancer”. Prostate, 2011, 48, 93.

[41] Widy-Kierska K., Roszkowski I.: “LDH activity in patients with ovarian tumors”. Obstet. Gynecol., 1968, 31, 243.

[42] Kucukgoz Gulec U., Paydas S., Guzel A.B., Buyukkurt S., Seydaoglu G., Vardar MA.: “Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia”. Med. Oncol., 2012, 29, 2937.

[43] Fujii S., Konishi I., Suzuki A., Okamura H., Okazaki T., Mori T.: “Analysis of serum lactic dehydrogenase levels and its isoenzymes in ovarian dysgerminoma”. Gynecol. Oncol., 1985, 22, 65.

[44] Boran N., Kayikçioğlu F., Yalvaç S., Tulunay G., Ekinci U., Köse M.F.: “Significance of serum and peritoneal fluid lactate dehydrogenase levels in ovarian cancer”. Gynecol. Obstet. Invest., 2009, 49, 272.

[45] Perkins G.L, Slater E.D., Sanders G.K., Prichard J.G.: “Serum tumor markers”. Am. Fam. Physician, 2003, 68, 1075.

[46] Djurdjevic S., Maksimovic M., Pantelic M., Golubovic A., Curcic A., Curcic A.: “Usefulness of beta hCG as tumor marker in the diagnosis and follow up of patients with ovarian cancer”. J. BUON., 2011, 16, 715.

[47] Panza N., Pacilio G., Campanella L., Peluso G., Battista C., Amoriello A., et al.: “Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta
chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma”. Cancer, 1988, 61, 76.

[48] Aggarwal P., Kehoe S.: “Serum tumour markers in gynaecological cancers”. Maturitas, 2010, 67, 46.

[49] Haibin Z., Yue J., Yaxian X.: “Primary yolk sac tumor of the omentum: a case report and literature review”. Eur. J. Gynaecol. Oncol., 2009, 31, 682.

[50] Muller C.Y., Cole L.A.: “The quagmire of hCG and hCG testing in gynecologic oncology”. Gynecol. Oncol., 2009, 112, 663.